Volume 153, Issue 6, Pages 1315-1325 (June 2018) β-Blockers in COPD  François Maltais, MD, Roland Buhl, MD, Andrea Koch, MD, Valeria C. Amatto, MD, Jim Reid, MBChB DipObs, FCCP, MPS, Lars Grönke, MD, Ulrich Bothner, MD, Florian Voß, PhD, Lorcan McGarvey, MD, Gary T. Ferguson, MD  CHEST  Volume 153, Issue 6, Pages 1315-1325 (June 2018) DOI: 10.1016/j.chest.2018.01.008 Copyright © 2018 The Authors Terms and Conditions

Figure 1 Consolidated Standards of Reporting Trials diagram by baseline β-blocker, including discontinuations and causes, for combined studies. AE = adverse event. CHEST 2018 153, 1315-1325DOI: (10.1016/j.chest.2018.01.008) Copyright © 2018 The Authors Terms and Conditions

Figure 2 Kaplan-Meier estimates of probability of COPD exacerbation across the 1-year study by β-blocker use at baseline (treated set), for combined data. Hazard ratio of time to first COPD exacerbation was calculated by using a Cox proportional hazards model adjusting for COPD treatment, sex, age, BMI, race (Asian vs non-Asian), Global Initiative for Chronic Obstructive Lung Disease stage, cardiac disorders, hypertension, angiotensin-converting enzyme inhibitors, angiotensin II antagonists, and lipid-modifying agents. CHEST 2018 153, 1315-1325DOI: (10.1016/j.chest.2018.01.008) Copyright © 2018 The Authors Terms and Conditions